Engineered immune cells take on Hard-to-Treat myeloma

NCT ID NCT03601078

Completed Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and control the disease. Researchers also looked at combining it with other drugs in certain groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bb2121 (a CAR-T cell therapy made from the patient's own immune cells, engineered to target and kill myeloma cells)

What this could lead to

If successful, this could provide a new treatment option for people with multiple myeloma that has come back or is hard to treat, potentially leading to better disease control.

What could go wrong

This is a Phase 2 study, so results are still early. The therapy may not work for everyone, and there are risks like severe side effects (e.g., cytokine release syndrome, nerve problems). Long-term benefits are not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Clinica Universidad de Navarra

Pamplona, 31008, Spain
Columbia University Medical Center/New York-Presbyterian Hospital

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215-5450, United States
Emory University School of Medicine

Atlanta, Georgia, 30322, United States
Froedtert Hospital BMT Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Kings College Hospital NHS Foundation Trust

London, SE5 9RS, United Kingdom
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Local Institution - 404

Poitiers, 86021, France
Local Institution - 505

Würzburg, 97080, Germany
Local Institution - 506

Hamburg, 20246, Germany
Local Institution - 603

Bologna, 40138, Italy
Local Institution - 704

Salamanca, 37007, Spain
MD Anderson Cancer Center The University of Texas

Houston, Texas, 77030, United States
Massachusetts General Hospital

Boston, Massachusetts, 02117, United States
Mayo Clinic in Arizona - Scottsdale

Scottsdale, Arizona, 85259, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Mt Sinai Medical Center - NY

New York, New York, 10029, United States
Swedish Cancer Inst

Seattle, Washington, 98104, United States
Tennessee Oncology PLLC

Nashville, Tennessee, 37203, United States
University Of California San Francisco Medical Center

San Francisco, California, 94143, United States
University Of Nebraska

Omaha, Nebraska, 68198-7680, United States
University Of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
Washington University

St Louis, Missouri, 63110, United States